Zhang Jiandong, Lv Yajuan, Chen Fangjie, Wang Xiaotong, Zhang Li, Zhang Xiaozhi
Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Ann Transl Med. 2021 Jan;9(2):166. doi: 10.21037/atm-21-184.
No clear guidelines or available studies exist regarding the effects of intensity-modulated radiotherapy (IMRT) of esophageal cancer (EC) on the cardiovascular system. We therefore analyzed a wide range of cardiac vascular dosimetric parameters and clinical characteristics to assess the prognostic factors for EC patients treated with IMRT.
A total of 112 patients receiving IMRT at the Qianfoshan Hospital between July 2012 and May 2017 were retrospectively reviewed. The dose per fraction was 1.8-2.0 Gy, and the total dose range was 54-66 Gy. Kaplan-Meier analysis was used to estimate death due to heart disease. Univariate and multivariate logistic regression models were calculated to test for associations between patient characteristics and dose-volume histogram (DVH) parameters. A -test and chi-squared or Fisher's exact test was used to analyze the comparisons.
The maximum and mean doses received by the heart were 57.34±13.51 and 24.83±11.40 Gy, respectively. Among the parameters examined, which included the maximum dose received by the heart, the mean dose received by the right and left ventricle (RV and LV), and the maximum dose received by the right atrium (RA), the mean dose received by the RV predicted survival and was included in our multivariate analysis. The results indicated that patients with basic heart disease who were undergoing concurrent radiochemotherapy were more likely to have cardiac disease.
This is first study to examine the prognosis of cardiovascular vessels exposed to various radiation doses during the treatment of EC, the findings of which suggest that limiting radiation exposure may be an important measure in IMRT application. These findings of this study may provide theoretical support for prediction of radiation-induced heart disease (RIHD). Furthermore, to curb the risk of RIHD, the modality of chemotherapy also needs to be attentively monitored and managed.
关于食管癌调强放疗(IMRT)对心血管系统的影响,目前尚无明确的指南或可用研究。因此,我们分析了一系列心脏血管剂量学参数和临床特征,以评估接受IMRT治疗的食管癌患者的预后因素。
回顾性分析2012年7月至2017年5月在千佛山医院接受IMRT治疗的112例患者。每分次剂量为1.8 - 2.0 Gy,总剂量范围为54 - 66 Gy。采用Kaplan-Meier分析估计心脏病导致的死亡情况。计算单因素和多因素逻辑回归模型,以检验患者特征与剂量体积直方图(DVH)参数之间的关联。采用t检验和卡方检验或Fisher精确检验进行比较分析。
心脏接受的最大剂量和平均剂量分别为57.34±13.51 Gy和24.83±11.40 Gy。在所检查的参数中,包括心脏接受的最大剂量、右心室和左心室接受的平均剂量以及右心房接受的最大剂量,右心室接受的平均剂量可预测生存情况,并纳入我们的多因素分析。结果表明,接受同步放化疗的有基础心脏病的患者更易患心脏病。
这是第一项研究食管癌治疗期间暴露于不同辐射剂量下心血管预后的研究,其结果表明限制辐射暴露可能是IMRT应用中的一项重要措施。本研究结果可为预测放射性心脏病(RIHD)提供理论支持。此外,为控制RIHD的风险,化疗方式也需要密切监测和管理。